Adaptive Biotechnologies Corp. (ADPT)
24.14
-0.52
(-2.11%)
USD |
NASDAQ |
Sep 03, 10:42
Adaptive Biotechnologies Research and Development Expense (TTM) : 80.01M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.01M |
| March 31, 2026 | 83.21M |
| December 31, 2025 | 83.81M |
| September 30, 2025 | 85.20M |
| June 30, 2025 | 86.41M |
| March 31, 2025 | 87.90M |
| December 31, 2024 | 94.33M |
| September 30, 2024 | 96.84M |
| June 30, 2024 | 97.90M |
| March 31, 2024 | 101.92M |
| December 31, 2023 | 101.58M |
| September 30, 2023 | 104.17M |
| June 30, 2023 | 111.67M |
| March 31, 2023 | 116.93M |
| December 31, 2022 | 122.54M |
| Date | Value |
|---|---|
| September 30, 2022 | 126.45M |
| June 30, 2022 | 128.29M |
| March 31, 2022 | 131.34M |
| December 31, 2021 | 129.66M |
| September 30, 2021 | 133.29M |
| June 30, 2021 | 129.34M |
| March 31, 2021 | 117.79M |
| December 31, 2020 | 108.57M |
| September 30, 2020 | 94.21M |
| June 30, 2020 | 84.78M |
| March 31, 2020 | 76.62M |
| December 31, 2019 | 66.06M |
| September 30, 2019 | 55.53M |
| June 30, 2019 | 44.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Personalis, Inc. | 56.12M |
| 10X Genomics, Inc. | 226.80M |
| Alamar Biosciences, Inc. (California) | 44.03M |
| Champions Oncology, Inc. | 9.084M |
| Medpace Holdings, Inc. | -- |